Gene expression profiles of NSCLC cells treated with almonertinib, paclitaxel, and their combination

Transcriptomic profiling revealed that the combination therapy elicits an unique molecular signature distinct from either monotherapy alone. We identified a specific gene cluster (C8) that was suppressed only by the drug combination, and mainly enriched in cell cycle, DNA replication and mitochondrial function in PC9 cells. The downregulation of these processes was validated in H1975 cells, and key genes (e.g., XRCC2, SKA3, TOMM40) also exhibited prognostic relevance. Overall design: The PC9 or H1975 cell lines treated under control, paclitaxel alone (0.3 nM for PC9; 1 nM for H1975), almonertinib (2 nM for PC9; 1 nM for H1975), and thepaclitaxel+almonertinib combination for 24 hours were collected and their RNAs were isolated using TRIzol reagent.